News from the ACC Annual Scientific Session 2016

Letter to Readers |
April 6, 2016

News from the ACC Annual Scientific Session 2016

NEJM Journal Watch and Physician's First Watch coverage of the meeting

This week, NEJM Journal Watch and Physician's First Watch have brought you coverage of study findings presented at the American College of Cardiology's 65th Annual Scientific Session & Expo, held in Chicago, IL. Here is a compilation of our coverage, listed by date and title of meeting presentations, with the articles' first authors in parentheses. (Your NEJM Journal Watch subscription is required, except where noted.)

Saturday, April 2, 2016

Partner 2: Transcatheter Aortic Valve Replacement Compared with Surgery in Intermediate Risk Patients with Aortic Stenosis: Final Results from the Randomized Placement of Aortic Transcatheter Valves 2 Study (Leon MB et al.)

NEJM Journal Watch coverage (free)

HOPE-3: Blood Pressure Lowering in People at Moderate Risk (Lonn EM et al.)

HOPE-3: Effects of Combined Lipid and BP-Lowering on Cardiovascular Disease in a Moderate Risk Global Primary Prevention Population (Yusuf S et al.; Yusuf S et al.)

NEJM Journal Watch coverage (free)

Physician's First Watch coverage (free)

Coming to Consensus on the Role of Non-Statin Therapies

Physician's First Watch coverage (free)

Sunday, April 3, 2016

GAUSS-3: Comparison of PCSK9 Inhibitor Evolocumab Versus Ezetimibe in Statin-Intolerant Patients: The Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin-Intolerant Subjects 3 (GAUSS-3) Trial (Nissen SE et al.)

NEJM Journal Watch coverage (free)

Isch MR: Two-Year Outcomes of Surgical Treatment of Moderate Ischemic Mitral Regurgitation: A Randomized Clinical Trial from the Cardiothoracic Surgical Trials Network (Michler RE et al.)

NEJM Journal Watch coverage

Surgery Ischemic HF: Ten-Year Outcome of Coronary Artery Bypass Graft Surgery Versus Medical Therapy in Patients with Ischemic Cardiomyopathy: Results of the Surgical Treatment for Ischemic Heart Failure Extension Study (Velazquez EJ et al.)

NEJM Journal Watch coverage

Monday, April 4, 2016

Resuscitation Outcomes: Antiarrhythmic Drugs for Shock-Refractory Out-of-Hospital Cardiac Arrest: The Resuscitation Outcomes Consortium Amiodarone, Lidocaine, or Placebo Study (Kudenchuk PJ et al.)

NEJM Journal Watch coverage

FIRE AND ICE: Largest Randomized Trial Demonstrates an Effective Ablation of Atrial Fibrillation: the FIRE AND ICE Trial (Kuck K-H et al.)

NEJM Journal Watch coverage

Rate v Rhythm: A Randomized Trial of Rate Control Versus Rhythm Control for Atrial Fibrillation After Cardiac Surgery (Gillinov AM et al.)

NEJM Journal Watch coverage

ATMOSPHERE: Direct Renin-Inhibition with Aliskiren Alone and in Combination with Enalapril, Compared with Enalapril, in Heart Failure (the ATMOSPHERE Trial) (McMurray JJV et al.)

NEJM Journal Watch coverage

LATITUDE-TIMI 60: The Losmapimod to Inhibit P38 MAP Kinase as a Therapeutic Target and Modify Outcomes After an Acute Coronary Syndrome (LATITUDE-TIMI 60) Trial: Primary Results of Part A (O'Donoghue ML et al.)

NEJM Journal Watch coverage

Your Comment

(will not be published)

Filtered HTML

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Do you have any conflict of interest to disclose?
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

* Required

Reader comments are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.